Supporting 0 to 1 (Idea to NewCo)
Biotech Startups
Viva Ventures Biotech Fund
We are a corporate VC fund that focuses on investments in global first-in-class, discovery-stage biotech startups with significant growth potential. Viva Ventures is one of very few biotech VCs that have extensive expertise and industry know-how for early stage investments.
Supporting Biotech Startups since 2008
Viva Ventures Biotech Fund is backed by the founders of top biotech startups and chief scientists of incubator centers, giving us access to the top startups around the world including Viva Biotech incubators, Boston CIC, and Hong Kong Science Park. Viva Ventures Fund I is purely financed by Dr. Jun Mao.
Our Strategies
Our Investment Thesis:
Early Stage = Achieve Superior Return
How to Achieve Higher Success Rate:
Genetic Linkage, Biomarkers and SBDD
Phase 2a/2 Clinical Success Rates
Impact of Structure-Based Drug Design (SBDD)
*Source: Nature Review, Volume 13, June 2014
-
Projects that showed greater confidence in target validation through human genetic target linkage to the disease were less likely to fail owing to a lack of efficacy
-
73% of projects with some genetic linkage of the target to the disease were active or successful in Phase II compared with 43% of projects without such data, also that of projects with biomarkers could exceed 80%
Deal Flow Funnel
Global Ecosystem for Deal Sourcing and Exiting
Global Pharmas and Biotech Companies Include:
Our Portfolio Overview
Diversified Portfolio
* Including all the projects invested by Fund I, Fund II and Fund III
Our Team
Fund Management
Jun Mao, PhD (UK)
Founder and Chairwoman
-
Founding Director of Viva Biotech, a HK listed company with 100X+ investment return
-
Active biotech investor since 2008, invested 13 biotech and drug discovery startups
-
Working at top tier IB in City of London 1996-2009 after Ph.D. in Theoretical Physics (UK)
Lou Tartaglia, PhD (US)
Partner
-
Former Partner at Third Rock Ventures, CEO of Solstice Biologics, General Manager at GeneLogic, and Vice President of Metabolic Diseases at Millennium Pharmaceuticals
About 30 Top GP Advisory Partners
-
20+ years top biotech VC and/or drug discovery businesses
Our partners have extensive experience & track record:
GP Advisory Partners’ Role
-
Deal Sourcing
-
Deal Evaluation
-
DD & Negotiation
-
Exit Support
GP Advisory Partners’ Profile
-
Inventors of listed/ clinical stage drugs
-
20+ years of experience in drug discovery
-
Diversified expertise
-
Carry sharing
-
None compete
-
Right of first to know
Contact Us
Send us a business plan
If you have a great early-stage biotechnological or pharmaceutical project align with our investment strategy, please send your business plan to . We look forward to it!